IPP Bureau
Biocon posts Q4 FY24 PAT at Rs. 135 Cr
By IPP Bureau - May 17, 2024
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Elinzanetant significantly reduces frequency and severity of hot flashes associated with menopause
By IPP Bureau - May 17, 2024
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
Cresset opens new new India HQ in Bengaluru to tap potential of APAC market
By IPP Bureau - May 17, 2024
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
Cipla invests additional Rs. 26 crore in Achira
By IPP Bureau - May 16, 2024
Achira is engaged in development and commercialization of PoC medical test kits in India
Granules India posts Q4 FY24 consolidated PAT at Rs. 129.64 Cr
By IPP Bureau - May 16, 2024
The company has posted net profit of Rs. 405.31 crores for the Financial Year ended March 31, 2024
Ind-Swift posts Q4 FY24 consolidated PAT at Rs. 37.53 Cr
By IPP Bureau - May 16, 2024
The company has posted net profit of Rs. 14.23 crores for the Financial Year ended March 31, 2024
Bayer starts Phase I study with novel targeted radionuclide therapy in advanced metastatic prostate cancer
By IPP Bureau - May 16, 2024
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
IOL Chemicals and Pharmaceuticals posts Q4 FY24 consolidated PAT at Rs. 27.62 Cr
By IPP Bureau - May 15, 2024
The company has posted net profit of Rs.134.43 crores for the Financial Year ended March 31, 2024
Thyrocare Technologies posts Q4 FY24 consolidated PAT at Rs. 17.78 Cr
By IPP Bureau - May 15, 2024
The company has posted net profit of Rs.70.76 crores for the Financial Year ended March 31, 2024
Gujarat Themis Biosyn posts Q4 FY24 PAT at Rs. 15.88 Cr
By IPP Bureau - May 15, 2024
The company has posted net profit of Rs. 59.16 crores for the Financial Year ended March 31, 2024
Merck discontinues Phase 3 KeyVibe-010 trial of coformulation of Vibostolimab and Pembrolizumab
By IPP Bureau - May 14, 2024
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
AbbVie and Gilgamesh Pharmaceuticals collaborate to develop next-gen therapies for psychiatric disorders
By IPP Bureau - May 14, 2024
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
Moderna update on investigational RSV vaccine
By IPP Bureau - May 14, 2024
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
Lonza reports softer performance in Q1 2024
By IPP Bureau - May 14, 2024
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
